Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Hold” by Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has earned a consensus rating of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.20.

Several brokerages have weighed in on GOSS. Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 target price for the company in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Monday, July 27th.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $0.17 on Friday. The firm has a market cap of $39.78 million, a PE ratio of -0.21 and a beta of 2.04. The firm has a 50 day simple moving average of $0.17 and a 200-day simple moving average of $0.74. Gossamer Bio has a 1-year low of $0.11 and a 1-year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $4.67 million. As a group, sell-side analysts expect that Gossamer Bio will post -0.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Gossamer Bio by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after acquiring an additional 598,981 shares during the period. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio in the first quarter worth approximately $3,363,000. State Street Corp grew its holdings in Gossamer Bio by 139.7% in the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares during the period. Geode Capital Management LLC increased its position in Gossamer Bio by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after purchasing an additional 183,183 shares during the last quarter. Finally, Corient Private Wealth LLC increased its position in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.